# Sponsor Sovereignty

In research funding governance, does the source of trial sponsorship determine the degree of scientific sovereignty available to African research institutions? This audit classified 23,873 African trials by sponsor origin using ClinicalTrials.gov lead-sponsor metadata through March 2026. Investigators reported the foreign-sponsor dependency ratio as the primary estimand for research sovereignty. Foreign pharmaceutical companies, academic institutions, and bilateral agencies collectively sponsored an estimated sixty-five percent of African trials, while African governments contributed fewer than eight percent and African private industry under three percent. The 11,599 trials registered in the most recent epoch (2021-2025) showed no significant change in the foreign-sponsor ratio compared to earlier periods. Without financial sovereignty, Africa cannot direct research toward its own priorities — 174 mental health trials versus 1,793 HIV trials reflects donor rather than local priorities. These findings demonstrate that funding dependency structurally constrains Africa's research agenda. Interpretation is limited by the single lead-sponsor attribution which may obscure complex funding arrangements.

## References

1. Lang T, Siribaddana S. "Clinical trials have gone global: is this a good thing?" PLoS Med. 2012;9:e1001228.
2. Alemayehu C, et al. "Behind the mask of the African clinical trials landscape." Trials. 2018;19:519.

## Note Block

- Type: research
- App: https://mahmood726-cyber.github.io/africa-e156-students/governance-justice/dashboards/sponsor-sovereignty.html
- Code: https://github.com/mahmood726-cyber/africa-e156-students/blob/master/governance-justice/code/sponsor-sovereignty.py
- Data: ClinicalTrials.gov API v2
- Date: 2026-04-05